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PU.1 regulates the commitment of adult 
hematopoietic progenitors and 
restricts granulopoiesis
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Li Wu, and Stephen L. Nutt
 
The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria 3050, Australia
 
Although the transcription factor PU.1 is essential for fetal lymphomyelopoiesis, we 
unexpectedly found that elimination of the gene in adult mice allowed disturbed 
hematopoiesis, dominated by granulocyte production. Impaired production of lymphocytes 
was evident in PU.1-deficient bone marrow (BM), but myelocytes and clonogenic 
granulocytic progenitors that are responsive to granulocyte colony-stimulating factor or 
interleukin-3 increased dramatically. No identifiable common lymphoid or myeloid 
progenitor populations were discernable by flow cytometry; however, clonogenic assays 
suggested an overall increased frequency of blast colony-forming cells and BM chimeras 
revealed existence of long-term self-renewing PU.1-deficient cells that required PU.1 for 
lymphoid, but not granulocyte, generation. PU.1 deletion in granulocyte-macrophage 
progenitors, but not in common myeloid progenitors, resulted in excess granulocyte 
production; this suggested specific roles of PU.1 at different stages of myeloid development. 
These findings emphasize the distinct nature of adult hematopoiesis and reveal that PU.1 
regulates the specification of the multipotent lymphoid and myeloid compartments and 
restrains, rather than promotes, granulopoiesis.
 
The multipotent hematopoietic stem cell (HSC)
undergoes progressive differentiation to pro-
duce all of the mature blood lineages. He-
matopoiesis is continuous throughout life, dy-
namic in its response to stress, and is located in
multiple anatomic sites. The current model of
adult hematopoiesis proposes that the HSC
generates the common myeloid progenitor
(CMP) that is able to differentiate into the
erythromyeloid lineages, and the common
lymphoid progenitor (CLP) that produces B,
T, natural killer, and dendritic cells (for review
see reference 1). The CMP is postulated to
form either of two more restricted cell types—
the granulocyte-macrophage progenitor (GMP)
or the megakaryocyte-erythrocyte progenitor
(MEP; reference 2). An important feature of
this model is that committed progenitors repre-
sent transit amplifying stages and are incapable of
self-renewal (2, 3). Hematopoiesis in the fetal
liver is less well-characterized, but also is
known to include distinct progenitor types,
such as bipotent B cell/macrophage and T
cell/macrophage progenitors (4–6). In support
of these ontogenic differences, several tran-
scription factors that are known to be essential
for embryonic hematopoiesis, including acute
myeloid leukemia (AML)-1 (7) and SCL (8),
display very different phenotypes when deleted
in adult mice. Hence, the extrapolation of data
on fetal hematopoiesis to the adult is problematic.
PU.1 is an extensively studied hematopoi-
etic-specific Ets family transcription factor that
is essential for embryonic lymphoid and myeloid
development (for review see reference 9).
Within adult hematopoietic progenitors, 
 
PU.1
 
is expressed in the HSCs and the earliest mye-
loid and lymphoid progenitors before being
down-regulated in MEPs. Upon lineage com-
mitment, 
 
PU.1
 
 is expressed highly by myeloid
cells, at low levels in B cells, and silenced in
the erythroid and T cell lineages (10). Recent
data has suggested that PU.1 is an important
tumor suppressor in murine, and possibly hu-
man, AML (11, 12). PU.1 is believed to play
these important roles by regulating numerous
genes within the myeloid and lymphoid lin-
eages, as well as by interacting with several
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Figure 1. Conditional deletion of 
 
PU.1
 
 
 
in adult hematopoiesis.
 
 
(A) The genomic locus of 
 
PU.1. 
 
Exons are represented as boxes; introns are 
represented as black lines; coding regions are in gray; nontranslated re-
gions are in white; arrows indicate the direction of translation. The alleles  
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other key transcription factors, such as interferon regulatory
factor (IRF)4, IRF8, AML-1, CCAAT/enhancer binding
protein 
 
 
 
 (C/EBP
 
 
 
), GATA-1, and c-Jun (13). Because re-
ported PU.1 target genes include 
 
M-CSFR, granulocyte col-
ony-stimulating factor
 
 (G
 
-CSF)R, GM-CSFR
 
 
 
 (14), and 
 
IL7R
 
 
 
(15), cytokine responsiveness is coupled to the action of this
developmentally essential transcription factor.
Mice that bear two different 
 
PU.1
 
 mutations have been
described extensively. Both lacked granulocytes and mac-
rophages (16, 17), but important differences were reported.
The mutant of Scott et al., which died in late gestation (be-
tween E17-18), lacked lymphocytes and long-term BM re-
populating activity (16, 18), whereas the mutant of Mc-
Kercher et al. was born alive and could live up to 2 wk on
antibiotics (17). Analysis of these pups revealed aberrant B
cell development; an abnormally large population of Mac-1
 
 
 
immature myeloid cells; and delayed, but normal, T lym-
phopoiesis. Recently, a third mutant was reported that died
at 1 d and had defects in erythroid progenitor self-renewal;
however, no data on its lymphoid and myeloid phenotypes
were reported (19). These studies demonstrate that PU.1 is
essential for normal fetal hematopoiesis, but do not address
its roles in adult hematopoiesis.
We developed a conditional mutation that allows inacti-
vation of 
 
PU.1
 
 in adult hematopoietic cells. We find that
 
PU.1
 
 ablation resulted in dramatically perturbed hemato-
poiesis and, contrary to expectation, greatly enhanced granu-
lopoiesis. These changes were accompanied by a marked
expansion in granulocytic progenitors, and loss of macrophage-
CSF (M-CSF), GM-CSF and IL-6 responsiveness, whereas
blast colony-forming capacity was preserved. Analysis of the
multipotent progenitors revealed that PU.1 deficiency re-
sulted in the loss of all FACS-identifiable lymphoid and my-
eloid progenitor populations. These results suggest that PU.1
is essential for normal transit through the CLP and CMP/
GMP stages of adult hematopoiesis where it promotes lym-
phopoiesis, and conversely, restricts granulopoiesis.
 
RESULTS
Generation and validation of a PU.1 conditional allele
 
The PU.1-targeting construct contained 
 
LoxP
 
 flanked 
 
PU.1
 
exon-5 followed by an 
 
frt
 
 flanked 
 
internal ribosome entry site
(IRES)-GFP
 
 cassette (Fig. 1 A). Homologous recombination
in embryonic stem (ES) cells was confirmed using Southern
hybridization and PCR genotyping, producing the 
 
PU.1
 
gfp
 
allele (Fig. 1, A–C). Germ-line transmission was achieved
with two independent ES cell clones with identical GFP ex-
pression and null phenotype. The GFP reporter allowed
detailed characterization of the 
 
PU.1
 
 expression domain,
which was reported elsewhere (10). The conditional 
 
PU.1
 
fl
 
allele was produced by breeding 
 
PU.1
 
gfp
 
 with a Flp recombi-
nase-expressing strain (Fig. 1 A).
To determine the phenotype of this 
 
PU.1
 
 mutation, we
bred the 
 
PU.1
 
gfp
 
 or 
 
PU.1
 
fl
 
 allele to the Deleter-Cre strain to
produce 
 
PU.1
 
 
 
gfp
 
 or 
 
PU.1
 
 
 
, respectively. Intercrossing of
 
PU.1
 
 
 
/
 
 
 
 mice resulted in no 
 
PU.1
 
 
 
/
 
 
 
 individuals at day 21,
whereas E18.5 
 
PU.1
 
 
 
/
 
 
 
 embryos were present at the ex-
pected frequency (
 
 
 
/
 
 
 
 
 
 
 
 13 [24%], 
 
 
 
/
 
 
 
 
 
 
 
 30 [57%], 
 
 
 
/
 
 
 
 
 
 
 
10 [19%]). Timed pregnancies were allowed to continue
to term, but 
 
PU.1
 
 
 
/
 
 
 
 pups died shortly after birth (unpub-
lished data). Analysis of 
 
PU.1
 
 
 
/
 
 
 
 E18.5 embryos revealed an
absence of myeloid (Mac-1
 
 
 
Gr-1
 
 
 
) lineage cells (Fig. 1 D).
Although 
 
PU.1
 
 
 
gfp/
 
 
 
 embryos had populations of GFP
 
high
 
myeloid and GFP
 
low
 
 B cells, as well as GFP
 
 
 
c-kit
 
 
 
 progeni-
tors, 
 
PU.1
 
 
 
gfp/
 
 
 
gfp
 
 embryos showed only a residual GFP
 
 
 
c-
kit
 
 
 
 population (Fig. 1 D). This null phenotype was most
similar to that of Scott et al. (16) and showed that PU.1 was
required for the existence of virtually almost all 
 
PU.1
 
-
expressing cells in the fetal liver.
 
PU.1 inactivation perturbs adult hematopoiesis
 
To delete 
 
PU.1
 
 conditionally in adult hematopoietic cells,
 
PU.1
 
fl/f
 
l
 
 mice were crossed to the IFN
 
  
 
-inducible 
 
MxCre
 
transgene, which can be activated efficiently by polyinosine-
polycytosine (polyIC; reference 20). 
 
PU.1
 
fl/fl
 
 MxCre
 
 
 
 and
 
MxCre
 
 
 
 mice were injected i.p. with polyIC at days 0 and 3
and analyzed 10–14 d after induction. Exon-5 deletion fre-
quency was monitored using a PCR assay on genomic DNA
and confirmed by Western blotting (Fig. 1, E and F). Typi-
cally, at day 10 after injection, the deletion frequency ap-
proached 100% in BM and was between 70–90% in spleen,
blood, and thymus (Fig. 1 E). In contrast to the loss of fetal
 
PU.1
 
-expressing cells, 
 
PU.1
 
-deficient adult BM contained a
population of uniformly GFP
 
high
 
 cells; this suggested that
PU.1 was not required for the survival of all adult hemato-
poietic cells (Fig. 1 G).
Analysis of 
 
PU.1
 
 
 
/
 
 
 
 mice at 2 wk after polyIC treatment
revealed several hematologic abnormalities. The BM con-
tained normal total cellularity but exhibited an increased pro-
portion of blast cells, and immature cells of the granulocyte
 
derived from the integration of the targeting vector and subsequent manip-
ulations are shown. pA, polyadenylation signal sequence; circles, 
 
frt
 
 sites; 
triangles, 
 
loxP
 
 sites; stop, stop codons in all reading frames; splice acc., 
splice acceptor. Targeted 
 
PU.1
 
gfp
 
 alleles can be converted by flp-mediated 
deletion to 
 
PU.1
 
fl
 
 or Cre deletion to 
 
PU.1
 
 
 
. The position and direction of 
the genotyping primers (
 
a–e
 
) and 
 
Eco RI
 
 sites are indicated. (B) Southern 
blot analysis of ES cell 
 
Eco RI
 
-digested DNA showing the wild-type (6.6 kb) 
and targeted (5.3 kb) alleles (C) PCR genotyping of tail DNA using the 
primer set 
 
a/b/c
 
 showing the correct amplification of the wild-type, 
 
PU.1
 
gfp
 
, and 
 
PU.1
 
fl
 
 alleles. (D) Flow cytometric analysis of E18.5 fetal liver 
from 
 
PU.1
 
 
 
gfp/
 
 
 
 intercrosses showing loss of myeloid cells in the absence 
of PU.1 and the GFP fluorescence in progenitors (c-kit
 
 
 
). (E) PCR showing 
the relative polyIC-inducible deletion of the 
 
PU.1
 
fl
 
 allele in vivo. Mice were 
injected with polyIC on days 0 and 3 and analyzed on day 10. DNA was 
amplified with the primer combination 
 
b/c/d
 
. (F) Western blot analysis of 
PU.1 of mice of the indicated genotypes. Equal loading was confirmed using 
 
 
 
-actin. PU.1 is not expressed in most thymocytes and demonstrates non-
specific antibody binding. (G) GFP fluorescence in adult BM. 
 
PU.1
 
 
 
gfp/
 
 
 
gfp
 
 
(
 
gfp/gfp MxCre
 
 
 
) and control (
 
gfp/
 
  
 
MxCre
 
 
 
) mice are shown at 2 wk 
after polyIC injection. 
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lineage (promyelocytes and myelocytes; Table I). Staining
with myeloid lineage markers showed that the mutant mice
had twice as many Gr-1
 
 
 
 cells as controls and were Mac-1
 
 
 
(Fig. 2 A). Genotype analysis of total BM, granulocytes, and B
cells revealed virtually complete gene deletion at this time
point (Fig. 2 D). Strikingly, almost all BM cells of 
 
PU.1
 
 
 
/
 
 
 
mice expressed Ly6C and c-kit, markers that are indicative of
myeloid precursors. This expansion of PU.1-deleted (Mac-1
 
 
 
)
granulocytic precursors in the BM also was apparent 8 wk
after the last polyIC injection. At this time point, some differ-
entiation of PU.1 wild-type cells can be seen by the reappear-
ance of a small number of Mac-1
 
 
 
 cells (Fig. 2 A). Although
Mac-1, F4/80, and Fc
 
 
 
RII/III staining was lost from 
 
PU.1
 
-
deleted hematopoietic organs (Fig. 2 A) which indicate effi-
cient gene deletion, morphologically recognizable monocytes
remained (Table I). In contrast to the expanded granulocytic
lineage population, B lymphocyte numbers were reduced
variably in the PU.1 /  BM at day 14, with most cells having
a preB cell phenotype (CD19 B220 IL7R  c-kit ) and dis-
playing complete deletion of exon-5 (Fig. 2, B and D).
PolyIC induces an IFN response that is particularly detrimen-
tal to BM B cell precursors (21). Therefore, the differences at
this early time point may represent differential repopulation of
the B lineage (after the IFN response) and a consequence of
excessive granulopoiesis in the BM. PU.1 /  BM also lacked
the nucleated erythroid cells that represented 17% of the con-
trol BM at 2 weeks (Table I). FACS analysis confirmed the
PU.1 /  BM to be markedly deficient in Ter119 CD71 
erythroblasts (Fig. 2 C). The loss of nucleated erythroid cells
also was evident in histologic sections of the mutant BM (Fig.
Figure 2. PU.1 inactivation results in relative expansion of granu-
lopoiesis. Representative analysis of the (A) myeloid, (B) B lymphoid, and 
(C) erythroid lineages from the BM of PU.1 /  (fl/fl MxCre ) and control 
(fl/fl MxCre-) mice. Mice were injected on days 0 and 3 with polyIC and 
analyzed after 2 or 8 wk. (D) PCR analysis showing the relative PU.1 dele-
tion of total BM and sorted cells of the indicated lineages 2 wk after polyIC 
treatment. B cells were identified as CD19 B220 , granulocytes as Gr1 . 
PU.1fl/  tail DNA was used as a control.JEM VOL. 201, May 2, 2005 1491
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3 A) and similarly apparent after 8 wk (Table I). Conversely,
nucleated erythroid cells were present in spleens of both ge-
notypes at 2 wk, but remained only in the PU.1 /  spleens at
8 wk after treatment (Table I). The presence of nucleated
erythrocytes in spleen at the early time point most likely re-
flected the response to polyIC treatment, whereas their long-
term presence in the case of PU.1 /  mice represented true
extramedullary hematopoiesis.
The spleen of PU.1 /  mice also contained increased
numbers of granulocytic cells, although their frequency was
variable (20–90% Gr-1 c-kit ; Fig. 3, B and C). In more se-
vere cases (Fig. 3, B and C), spleen histology showed homo-
geneous infiltration by immature granulocytic forms and loss
of splenic architecture. PCR analysis confirmed complete
deletion of exon-5 in splenic granulocytes (Fig. 3 C).
Absolute spleen lymphocyte numbers were relatively
normal in most mice with a two- to threefold percentage
decrease in individuals with the most pronounced granulo-
cyte expansion (Table I and Fig. 3, A–C). PU.1 deletion in
the splenic lymphocytes was less frequent (50–70%), al-
though sorting of PU.1 / gfp mature B cells based on GFP
expression (that increases upon exon-5 deletion [Fig. 1 G])
showed that all GFPhigh cells were PU.1 deficient (Fig. 3 C).
Granulocyte maturation in the absence of PU.1
The expanded number of morphologically identifiable granulo-
cytes suggested that in contrast with fetal development, PU.1 is
not required for the differentiation of this lineage in vivo. To
examine the maturation of PU.1-deficient granulocytes, Gr-1 
BM cells were cultured for 7 d in G-CSF before being sub-
jected to flow cytometry, cytospin, and molecular analysis. In
agreement with the loss of Mac-1  staining, PU.1 /  granulo-
cytes represented a pure population of deleted cells (Fig. 3 D).
PU.1 /  granulocytes, in contrast with wild-type controls,
maintained c-kit expression and displayed some, but not com-
plete, maturation as measured by morphologic criteria (Fig. 3
Table I. Cellular analysis of hematological organs
2 wk after induction 8 wk after induction
Parameter PU.1fl/fl MxCre  PU.1fl/fl MxCre  PU.1fl/fl MxCre  PU.1fl/fl MxCre 
n   5n    5n    3n    3
Peripheral blood
Total cells 3,230   1,660 4,350   2,340 4,343   2,759 8,420   5,274
Neutrophils 160   280 850   370 36   35 407   230
Lymphocytes 2,910   1,330 2,870   1,340 3,403   1,442 7,513   4,702
Monocytes 100   70 590   750 237   251 310   185
Eosinophils 50   100 30   50 0   0 183   275
Platelets  10 5 6.3   1.0 10.7   3.3 13.7   2.1 9.5   2.1
Hematocrit % 44   3 43   3 43   3.6 46   1.2
Spleen
Weight mg 149   46 110   18 138   2.2 95.3   15
Blast cells 5   23    12    04    0.6
Myelocytes 3   21    11    10
Neutrophils 3   15    45    21    1
Lymphocytes 59   16 59   14 60   16 89   0.6
Monocytes 2   24    31    02    2
Eosinophils 1   11    1 0.3   0.6 0.3   0.6
Nucleated erythroid 26   12 27   12 31   13 3.7   2.3
Bone marrow
Total cells  10 6 44.4   8.5 42.3   6.0 37.9   5.6 33.4   1.5
Blast cells 9   53    07    1 4.3   1.2
Myelocytes 25   49    5 14   0.6 10   3.6
Neutrophils 45   5 48   12 49   16 35   4.4
Lymphocytes 14   6 12   10 19   10 23   2.1
Monocytes 7   58    4 5.7   2.5 9.7   1.2
Eosinophils 0   03    2 0.3   0.6 2   1
Nucleated erythroid 0.4   0.6 17   9 5.7   9.8 16   5.5
Data are the mean values   SD. n = 5 mice for 2-wk and n = 3 mice for 8-wk postinduction experiments. Peripheral blood values are per microliter. Total BM cells are per femur. 
Cellular differentials for BM and spleen are shown as percentages. Myelocytes include promyelocytes and myelocytes. Neutrophils include metamyelocytes, band neutrophils, 
and neutrophils.PU.1 REGULATES ADULT MULTIPOTENT PROGENITORS | Dakic et al. 1492
Figure 3. Perturbed granulocytic differentiation in the absence 
of PU.1. (A) Histologic section of day 21 BM from mice of the indicated 
genotype. Insets show cytocentrifuge preparations of corresponding 
BM. (B) Histologic section of relatively mild and severe granulocytic 
infiltrations in the spleen at day 21. (C) Severe PU.1 /  (fl/fl MxCre ) 
mice display splenomegaly and enhanced percentage of Gr-1 Mac-1  
cells by flow cytometry. PCR showing efficient deletion of PU.1fl and 
PU.1gfp alleles in 2-wk spleen of a PU.1 / gfp (fl/gfp MxCre ) mouse. Total, 
total splenocytes; Gr, Gr-1  cells; B, CD19 B220  B cells; T, CD3  
T cells; Er, CD71 Ter119  nucleated erythrocytes. B cells also were gated 
on GFPhigh (BGhi) or GFPlow (BGlo). The fl and gfp alleles were amplified 
with the primer combination b/c/d and e/c/d, respectively. (D) Control 
(fl/fl MxCre-) and PU.1 /  (fl/fl MxCre ) granulocytes were grown in 
G-CSF for 7 d before being analyzed by flow cytometry and morphology. 
PCR analysis showed the complete PU.1 deletion of cultured granulo-
cytes. (E) BM Gr-1hi cells were sorted and analyzed by RT-PCR for the 
expression of granulocytic enzymes, myeloperoxidase (MPO), LF, 
and gp91.JEM VOL. 201, May 2, 2005 1493
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D). RT-PCR analysis of the sorted Gr-1hi cells revealed that the
primary granule component, myeloperoxidase, as well as the sec-
ondary granule component, lactoferrin (LF), were expressed nor-
mally, whereas the putative PU.1 target gene and component of
nicotinamide adenine dinucleotide phosphate oxidase, gp91
(22), was down-regulated (Fig. 3 E). The normal expression of
LF contrasted with the absence of this transcript in PU.1 /  fe-
tal liver-derived cultures (30). These data suggest that PU.1 / 
granulocytes were capable of aberrant, and possibly delayed, dif-
ferentiation to relatively mature cells (Fig. 3, A inset, D, E), de-
spite the reported requirement for PU.1 in the transcription of a
variety of genes that is required for granulocyte function.
Expanded clonogenic granulocyte progenitors in the absence 
of PU.1
Progenitor cells in the BM and spleen of PU.1 /  mice were
analyzed at 2 and 8 wk after PU.1 ablation, using agar cul-
tures and a range of stimulating factors. At the earlier time
point, the mutant BM was grossly depleted in cells that were
able to respond to GM-CSF or M-CSF by forming colonies
or clusters (Table II). In sharp contrast, PU.1 /  cultures that
were stimulated by G-CSF developed greatly elevated num-
bers of granulocytic colonies, the cells of which showed
some morphologic maturation (Fig. 3 D). Excessive numbers
of granulocytic colonies also developed in cultures that were
stimulated by IL-3 or stem cell factor (SCF; c-kit L), al-
though a few macrophage-containing colonies did develop
in IL-3–stimulated cultures. In contrast with the excessive
granulocyte colony numbers that developed with G-CSF,
virtually no colonies arose in response to IL-6. Moreover,
the PU.1 /  BM lacked eosinophil colony-forming cells that
were responsive to GM-CSF, IL-3, or IL-5 (Table II). In
cultures that were stimulated by the optimal growth factor
combination for megakaryocyte colony formation (SCF  
Table II. In vitro analysis of bone marrow colony-forming progenitors
Mean no. of colonies
Genotype
(n   4) Stimulus Blast G GM M Eo Meg
PU.1fl/fl MxCre  GM-CSF 2   2 0.3   0.5 4   60    0
G-CSF 83   31 0   00    0
M-CSF 0.5   1.0 0   0 1.5   2.4
IL-3 12   12 152   15 2   16    50    0 0.5   1.0
SCF 5   5 29   80    00    0
IL-6 0.8   0.7 0   00    0
SCF   G-CSF 3   4 129   15 0   00    0
FL   LIF 0   0 0.2   0.2 0   00    0
IFN  14   11 0   00    0
EPO 0.1   0.1
TPO 1   1
SCF   IL-3   EPO 6   9 178   51 7   54    40    02    1
saline 0.8   1.0 0   00    0
PU.1fl/fl MxCre  GM-CSF 19   54    4 31   13 3   2
G-CSF 10   3 0   02    3
M-CSF 1   15    3 69   29
IL-3 8   7 18   6 11   5 27   92    14    3
SCF 5   3 14   71    11    1
IL-6 8   41    1 0.5   0.6
SCF   G-CSF 7   3 18   11 3   23    3
FL   LIF 2   1 0.8   0.5 0   0 0.1   0.3
IFN  3   20    00    0
EPO 5   2
TPO 2   1
SCF   IL-3   EPO 7   3 21   8 11   6 24   92     1 16   6
saline 0   00    00    0
Bone marrow of PU.1    (fl/fl MxCre ) and control (fl/fl MxCre ) mice was analyzed on day 14 after induction. 25,000 cells were cultured in agar with the indicated cytokines 
for 7 d, stained, and counted. Experiments were performed using four separate mice and quadruplicate cultures for each stimulus. Numbers represent mean colony numbers 
from four mice   SD. Values in bold highlight examples of increased numbers of committed colony-forming progenitors responsive to selected growth factors or growth factor 
combinations after PU.1 deletion.
Eo, eosinophil colony; FL, FH3 ligand; G, granulocyte colony; GM, granulocyte/macrophage colony; M, macrophage colony; Meg, megakaryocyte colony; TPO, thrombopoietin.PU.1 REGULATES ADULT MULTIPOTENT PROGENITORS | Dakic et al. 1494
IL-3   erythropoietin [EPO]), few or no megakaryocyte
colonies developed in cultures of PU.1 /  BM cells. PCR
analysis of BM (Fig. 2 D) and individual colonies (n   81)
showed the nearly total deletion of exon-5; this confirmed
that any colony formation was the result of PU.1-deficient
progenitors (unpublished data).
Analysis of clonogenic BM progenitors 8 wk after
polyIC treatment showed a similar trend toward excess gran-
ulocytic progenitor numbers. However, G-CSF–responsive
progenitors were present in only slightly higher numbers (fl/
fl 8.6   3.8,  /  16   4.7), whereas IL-3 (fl/fl 15   10,
 /  95   22), SCF/G-CSF (fl/fl 20   5.0,  /  48   13),
and SCF/IL-3/EPO (fl/fl 16   3.6,  /  97   8.9) cultures
generated increased numbers of granulocytic colonies
(mean   SD; n   3 for each genotype).
At 2 wk after polyIC treatment, the spleen in control
mice was enlarged and contained elevated numbers of col-
ony-forming cells. Strikingly, mutant spleen cells generated
vastly increased numbers of granulocytic colonies (Table
III), excessive numbers of megakaryocytic colonies, and, in-
terestingly, IL-3–responsive macrophage-containing colo-
nies. These data demonstrate that PU.1 deficiency induced
extramedullary hematopoiesis that, similarly to BM, resulted
in excessive granulopoiesis. The spleen also contained sig-
nificant numbers of IL-3, but not M-CSF–responsive mac-
rophage colony-forming cells. This was despite the fact that
the deletion frequency was high and no Mac-1  cells were
present (Fig. 3 C; Table III). This effect largely was tran-
sient because many fewer clonogenic cells were found in
the spleen at the 8-wk time point. However, increased
SCF/IL-3/EPO–responsive granulocyte (fl/fl 1   1,  / 
25   7.2) and megakaryocyte (fl/fl 3.7   2.9,  /  12  
7.5) colonies were still present in the mutant spleens; this
was indicative of ongoing hematopoiesis (mean   SD; n  
3 for each group). Collectively, these data demonstrate that
PU.1 inactivation resulted in rapid and dramatic changes in
the responsiveness, number, and anatomic location of he-
matopoietic progenitors.
PU.1 is required for the balanced production of multipotent 
bone marrow progenitors
To determine directly the effect of PU.1 deletion on defined
BM progenitors, we isolated lineage-negative (lin ) cells 2 wk
after Cre activation, a time point when gene deletion is essen-
tially complete (Fig. 4 B). PU.1 deficiency resulted in a dra-
matic loss of any readily identifiable lymphoid and myeloid
progenitor or stem cell populations (Fig. 4 A). Lin  cells were
c-kit /Sca1 /IL-7R  /CD34 /Fc RII/IIIlow, a phenotype
that is not defined by the existing progenitor scheme (Fig. 4
A). Morphologic analysis of sorted lin  cells revealed a high
proportion of blast cells in either genotype with a slightly
higher proportion in the S G2 M phases of the cell cycle in
the PU.1 /  preparations (Fig. 4 B). All PU.1 /  lin  cells ex-
pressed high levels of GFP, which indicated that such cells can
survive in the absence of PU.1 (Fig. 4 A) and contrasts with a
report that PU.1 positively regulates its own promoter (23).
RT-PCR analysis of lin  BM cells revealed that PU.1-
deficient cells had little M-CSFR, GM-CSFR , or IL-5R 
expression, and also lacked IL-6R  and gp130, the common
component of the IL-6R and leukemia inhibitory factor
(LIF) receptor (Fig. 4 C). It also was of note that PU.1 / 
cells showed decreased expression of a variety of important
transcription factors that have been shown to interact func-
tionally with PU.1, including GATA-1 and IRF-8 (Fig. 4
C). The levels of GATA-1 and IRF-8 most likely reflected
the expansion of the granulocytic lineage and absence of nu-
cleated erythrocytes in BM. The possibility that the Ets fam-
ily members, Spi-B or Spi-C, compensate for some PU.1
functions was excluded because neither was expressed in
PU.1 /  lin  BM. Several other critical genes, such as GM-
CSFR , IL-2R , GATA-2, and ikaros, were similarly ex-
pressed in cells of both genotypes (Fig. 4 C). Thus, in agree-
ment with the altered in vitro growth characteristics, PU.1 / 
progenitors displayed specific alterations in their transcrip-
tional profile as compared with wild-type cells.
The apparent loss of FACS-identifiable progenitors sim-
ply could be the consequence of the loss of expression of pu-
Table III. In vitro analysis of spleen colony-forming progenitors
Mean no. of colonies
Genotype
(n   4) Stimulus Blast G GM M Eo Meg
PU.1fl/fl MxCre  G-CSF 118   96 2   21    1
IL-3 26   26 269   200 27   18 59   38 0   0 19   14
SCF   IL-3   EPO 16   21 247   154 28   20 60   47 0   0 74   52
PU.1fl/fl MxCre  G-CSF 3   5 0   00    0
IL-3 1   2 7   11 4   5 10   11 0.5   1.0 0.8   1.0
SCF   IL-3   EPO 2   2 11   11 5   5 6   6 0.5   0.6 11   9
Mice were treated identically to those in Table II. Each culture contained 50,000 spleen cells. Numbers represent the mean   SD of colony counts from four mice of each genotype. 
Values in bold highlight examples of increased numbers of committed colony-forming progenitors responsive to selected growth factors or growth factor combinations after 
PU.1 deletion.
Eo, eosinophil colony; G, granulocyte colony; GM, granulocyte/macrophage colony; M, macrophage colony; Meg, megakaryocyte colony.JEM VOL. 201, May 2, 2005 1495
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tative PU.1 target genes, such as IL-7R  (15) and Fc RIIIa
(24). To overcome this uncertainty and to determine the
source of the excess granulocytic cells that were observed,
we sorted myeloid progenitors at short time intervals after
PU.1 deletion. Mice were injected with polyIC 36 h and 24 h
before the isolation of the defined myeloid and erythroid
progenitors. This short time frame was sufficient for efficient
deletion of exon-5 in CMP and GMP, but not for the loss of
the critical cell surface markers (Fig. 5). At this stage, cre -
sorted CMP and GMP populations were morphologically
indistinguishable from their cre  counterparts (Fig. 5). Analy-
sis of the in vitro clonogenic potential of sorted CMPs and
GMPs confirmed the efficient PU.1 inactivation, because
virtually no M-CSF–responsive colonies were obtained from
PU.1 /  progenitors (Fig. 5). Although the number of gran-
ulocyte colonies was relatively similar from PU.1fl/fl and
PU.1 /  CMPs (see G-CSF, IL-3, or IL-3/SCF/EPO), the
corresponding cultures of GMPs showed a pronounced en-
hancement of PU.1-deleted granulocyte colonies. As ex-
pected, sorted MEP gave rise to very few myeloid colonies
in these assays (unpublished data). These data suggest that the
enhanced granulopoiesis that was observed in the absence of
PU.1 is derived from increased/deregulated differentiation
capacity of the GMP, but not the more multipotent CMP.
These experiments gave two additional unexpected find-
ings. First, in contrast with the loss of GM-CSF–responsive
Figure 4. PU.1 is essential for multipotent lymphoid and myeloid 
progenitors. (A) BM lin  cells from 2-wk PU.1 /  (fl/fl MxCre ) and con-
trol (fl/fl MxCre ) polyIC-treated mice were assayed for HSC and lymphoid 
and myeloid progenitors. For GFP analysis, PU.1 gfp/  (PU.1gfp/flMxCre ) or 
control (PU.1gfp/flMxCre-) mice were treated as above. (B) Cytocentrifuge 
preparation and cell cycle analysis of lin  cells. Inset: PCR showing com-
plete deletion of exon-5 in lin  cells. Range of cycling cells (S G2 M) 
observed from two experiments is indicated. (C) RT-PCR for key hemato-
poietic regulators and PU.1 target genes in lin  and total BM. HPRT was 
used as a control for cDNA input.  RT, no reverse transcriptase was used 
in the reaction. Samples were taken at four cycle intervals. Ikaros isoforms 
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colonies 2 wk after Cre induction, short-term PU.1-deleted
GMPs generated excess granulocyte colonies when stimulated
with GM-CSF (Fig. 5). A similar trend was seen with total
BM cells at this short time point (fl/fl 21.2   6.1,  /  32.9  
12; mean   SD; n   3). We interpret this responsiveness to
GM-CSF to indicate that PU.1 may be critical for the expres-
sion of the GM-CSFR  between HSC and CMP stages (as
assayed at the 2-wk time point), but not for the maintenance
of its expression in the more mature GMPs (which only can
be assayed with short time points before new GM-CSFR –
negative GMPs are generated from HSC/CMP). Second, de-
spite the lack of M-CSF responsiveness, macrophage colonies
developed in IL-3 or IL-3/SCF from PU.1 /  CMPs, but not
GMPs; this suggests that PU.1 loss may have resulted in an
earlier than normal switch to granulocyte commitment in this
sequence of amplifying myeloid progenitors.
Figure 5. PU.1 regulates granulocyte production from the GMP. 
BM lin  cells from 36-h post-polyIC treatment PU.1 /  (fl/fl MxCre ) and 
control (fl/fl MxCre ) mice were assayed for erythromyeloid progenitors. 
Sorted CMP and GMP using the indicated gates were subjected to PCR for 
PU.1 exon-5 deletion. Cytocentrifuge preparations were stained with May-
Grunwald-Giemsa. Sorted cells were cultured in the indicated cytokines 
for 7 d, stained, and counted. 100 cells were plated in quadruplicate for 
each stimulus. Numbers represent the mean   average deviation from 
three independent experiments.JEM VOL. 201, May 2, 2005 1497
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PU.1-deficient stem cells do not generate lymphoid progeny
It has been reported that PU.1 /  fetal liver stem cells are un-
able to reconstitute adult hematopoiesis (18). However, given
our data showing the abundance of PU.1-deficient cells in
adult organs, we reinvestigated this issue using BM chimeras.
Ly5.1 mice were reconstituted with PU.1fl/fl MxCre  (Ly5.2)
and competing Ly5.1 BM cells. After 6 wk, relative reconstitu-
tion was assessed by analysis of peripheral blood. PU.1 inacti-
vation was then induced by polyIC and mice were analyzed at
6, 12, and 24 wk after deletion. Because PU.1 is required for
expression of CD45 (Ly5) (25, 26) and Mac-1 (27) in myeloid
cells, we used the absence of these markers to determine the
efficiency of PU.1 deletion in the reconstituting donor cells
(Fig. 6 A). A small number of nondeleted PU.1fl/fl Ly5.2  cells
could be distinguished easily from the other populations (Fig. 6
A). PCR analysis on DNA from total hematopoietic tissues or
sorted Ly5.1  (donor) and Ly5.1  (wild-type competitor) BM
cells for  , fl, and   (WT) alleles confirmed the validity of this
strategy (Fig. 6 B). Unexpectedly, PU.1 /  Ly5.1  cells gener-
ated significant BM cellularity at all time points (Fig. 6 C). Up
to 80% of BM Ly5.1  cells expressed the marker combination
Gr-1 c-kit  and were proliferating; this was indicative of con-
Figure 6. Competitive BM reconstitution. (A) PU.1fl/fl MxCre  BM was 
mixed with Ly5.1 BM (2:1 ratio) and used to reconstitute lethally irradiated 
Ly5.1 mice. The degree of reconstitution was assessed from peripheral 
blood after 6 wk, followed by the induction of PU.1 deletion by polyIC. 
Flow cytometric analysis of spleen from chimeric mice at 24 wk. Ly5.1  
cells were almost entirely PU.1-deficient granulocytes (Gr-1 Mac-1 ), 
whereas Ly5.1  competitors were Gr-1 Mac-1  (macrophages/granulo-
cytes) and CD19 Ly5.2  (B cells). c-kit CD71  erythroid progenitors were 
present in both populations. (B) BM, thymus, spleen, and blood cells and 
sorted Ly5.1  and Ly5.1  BM cells were subjected to PCR for PU.1 exon-5 
deletion. PU.1fl/ , PU.1fl/ , and PU.1 /  tail DNA was used as a control. ( ) 
Competitor Ly5.1  DNA. Note that the synthesis of   (WT) allele PCR 
product is more efficient that that of   allele and cannot be used for rela-
tive quantification of host/donor cellular contribution to chimerism. 
PU.1 /  was amplified from the BM, whereas no PU.1-deleted cells were 
found in the thymus, spleen, or blood. (C) The percentage of PU.1 /  cells 
in hematopoietic organs was determined at 6, 12, and 24 wk after polyIC 
injection. Total PU.1 /  cells (Ly5.1 ) are shown relative to Ly5.1  cells. The 
numbers have been normalized for the predeletion reconstitution fre-
quency. Because cells lose CD45 expression in some lineages, mutant cells 
were defined as Ter119 Ly5.1 .PU.1 REGULATES ADULT MULTIPOTENT PROGENITORS | Dakic et al. 1498
tinuing granulopoiesis. In addition to granulocytes, CD71 c-
kit  erythroid precursors were detected (Fig. 6 A). On differ-
ential count, these Ly5.1  BM cells had the same increase in
blast cells and immature granulocytes as BM of nonchimeric
PU.1-deficient mice (unpublished data). PU.1-deficient pro-
genitors also essentially were unable to contribute to T or B
lymphopoiesis (Fig. 6 A). PU.1-deficient granulocytes were
unable to compete with wild-type cells to repopulate blood
and spleen; this effect also was observed in the peripheral blood
of nonchimeric PU.1-deficient animals (Table I). Thus, in
contrast to reconstitution of irradiated recipients with PU.1 / 
fetal liver (18) or PU.1 /  BM deleted stem cells (unpublished
data), PU.1 deletion in steady-state hematopoiesis produced
mutant stem cells with long-term erythromyeloid cell produc-
tion capacity that is biased toward the granulocyte lineage.
DISCUSSION
PU.1 deficiency results in enhanced granulopoiesis
The most striking abnormality of PU.1-deficient BM was the
overwhelming granulopoiesis that virtually excluded other
lineages. This phenotype was surprising as it contrasted with
the lack of granulocytes in PU.1 /  fetal livers (16, 17). The
cells expressed markers indicative of an immature granulocyte
(c-kit, Ly6C) but not the PU.1 target Mac-1 (Fig. 2 A) and
appeared to undergo perturbed maturation in vivo (Fig. 3 A).
Previous studies on PU.1-deficient fetal liver (28) or neonates
(29–31) indicated that the hematopoietic progenitors lacked
G-CSF responsiveness ex vivo, but could be grown in IL-3.
These studies are complicated by the distinct phenotypes ob-
served in these strains that have not been satisfactory ex-
plained (32). The germ-line mutation reported here most re-
sembles the more severe phenotype of Scott et al. (16), in that
the mice die at birth and lack granulocytes, whereas the phe-
notype of McKercher et. al. is relatively less severe and results
in postnatal lethality and the development of some immature
granulocytes (17). The granulocytes shown here, although
displaying some morphologic maturation and expression of
G-CSFR and primary and secondary granules, clearly were
aberrant in their differentiation in that they maintained c-kit
expression. This phenotype was strikingly different than the
lack of fetal liver granulocytes, and suggested that in adults,
PU.1 suppressed the formation of granulocytic progenitors,
and subsequently, was required for their final functional mat-
uration. Heightened in vitro granulocyte response and a cor-
responding BM neutrophilia also were reported for mice
with conditional deletions of SOCS3 (33) and STAT3 (34),
but in contrast to the PU.1 mutation, the cells in both of
these mutants were hyperresponsive to G-CSF in vitro.
The analysis of clonogenic progenitors from mutant BM
and spleen demonstrated that multiple dramatic changes oc-
curred in the absence of PU.1, paralleling the hematologic
aberrations that were observed in vivo. These included a
marked loss of clonogenic cells that were responsive to GM-
CSF or M-CSF. In sharp contrast, granulocyte progenitors
occurred at abnormally high frequency in the BM and
spleen; this provided a basis for the enhanced granulopoiesis
that was observed in these tissues. Although the granulocytic
population exhibited full dependency on growth factors for
proliferation, the clonogenic cells exhibited several abnor-
malities, including heightened responsiveness to IFN  and a
failure to respond to IL-6, an agent with actions similar to
G-CSF when acting on normal granulocytic progenitor
cells. In contrast to granulopoiesis, the loss of cells that were
responsive to M-CSF and GM-CSF was identical to that re-
ported previously and is likely due to the induced failure of
existing and newly-formed cells to express the cognate re-
ceptors, as was noted previously in fetal PU.1 /  cells (28).
Although GM-CSF and M-CSF are the only known stimuli
for macrophage formation in vivo (35), we observed the
growth of IL-3–stimulated macrophage colonies from PU.1-
deficient cells; this indicated that macrophage development
may not be lost. This finding also was supported by the pres-
ence of almost normal numbers of BM monocytes 8 wk after
the induction of PU.1 deletion (Table I).
Within the erythroid and megakaryocytic cell lineages,
the PU.1-deficient adult phenotype was complex because
the pronounced loss of clonogenic cells and nucleated eryth-
rocytes from the BM was mirrored by increased erythrome-
gakaryopoiesis in the mutant spleen (Table III). Such ex-
tramedullary hematopoiesis has been observed in other
situations in which granulocyte cells become dominant in
the BM (36, 37). The presence of erythromegakaryocytic
colonies in the spleen contrasted with the loss of responsive-
ness to EPO   SCF or IL-3 (38) and the premature terminal
differentiation (19) that was reported for PU.1 /  fetal liver
erythroid progenitors; this highlighted another difference
between fetal and adult hematopoiesis.
B lymphocyte numbers were reduced, but not elimi-
nated, in the BM after gene inactivation which suggests a
role for PU.1 in B lymphopoiesis. However, the interpreta-
tion of these results is problematic because polyIC treatment
results in a transient-type I IFN response that was demon-
strated to reduce BM B cell numbers by  80% (21). After 8
wk, B and T cells were still identifiable in BM and spleen;
however, we were unable to determine if these were surviv-
ing mature lymphocytes and progeny of their homeostatic
proliferation; lymphocytes that were generated from a wave
of intermediate precursors, such as those preB cells seen 2
wk after PU.1 deletion; or lymphocytes that developed from
early lymphoid progenitors. To better assess lymphoid de-
velopment, we performed BM reconstitution in the pres-
ence of wild-type competitors (Fig. 6). These experiments
demonstrate that PU.1-deficient lymphopoiesis was incapa-
ble of producing B or T cells in this environment. There-
fore, we propose that the decrease in B cells in PU.1-defi-
cient BM reflected a defect in the production of early
lymphoid progenitors, potentially via the regulation of the
IL-7R  (15) and not a defect in mature B cell survival. This
conclusion is supported by the normal development of
PU.1fl/fl B cells when Cre expression was driven from theJEM VOL. 201, May 2, 2005 1499
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committed B cell–specific CD19 regulatory sequences (un-
published data). In summary, we propose that PU.1 regulates
B and T lymphopoiesis by controlling the commitment of
multipotent progenitors and not through the regulation of
lymphopoiesis directly.
PU.1 regulates the differentiation of multipotent lymphoid 
and myeloid progenitors
The enhanced BM granulopoiesis and highly aberrant in
vitro clonogenic responses that were observed in the absence
of PU.1 suggested that PU.1 regulated the balanced genera-
tion of multipotent myeloid progenitors (CMP and GMP) or
significantly changed their developmental potential. Analysis
of mutant BM indicated that the lin  compartment contained
a uniform population of c-kit  cells with blast-like morphol-
ogy that lacked all other commonly used markers to isolate
multipotent progenitor cells prospectively (Fig. 4 A). This
observation, combined with the presence of the most primi-
tive blast colony-forming cells in BM (Table II) and spleen
(Table III), the enhanced numbers of day 12 CFU-spleen
(not depicted) and the ability of PU.1 /  BM to reconstitute
granulo- and erythropoiesis for at least 24 wk (Fig. 6), sug-
gested that PU.1 was not required for stem cell function, but
for the balanced commitment of the immediate downstream
progenitors. In vitro analysis of defined myeloid progenitor
populations that were isolated immediately after PU.1 inacti-
vation supported this model because CMPs gave rise to rela-
tively normal numbers of colonies, whereas GMPs had mark-
edly increased granulocytic potential. Taken together, these
data demonstrate that the neutrophilia that was observed in
the PU.1-deficient mice arose as a result of deregulated pro-
duction of GMP-derived granulocytes. A mechanical expla-
nation for this observation could be that after loss of PU.1, a
switch to granulocytic commitment occurs earlier in the
pathway of transient amplifying myeloid progenitors that
favors the granulocytic lineage over the monocyte fate.
Immediately after PU.1 deletion, CMPs can still support
macrophage development in response to IL-3, whereas this
potential is lost prematurely in GMPs (Fig. 5). A switch from
macrophage to granulocytic differentiation also has been ob-
served in the absence of the PU.1-interacting partner IRF-8
(IFN consensus sequence-binding protein); this suggests that
this interaction also is important in vivo (13, 39).
Recently, it was reported that the targeted deletion of
regulatory enhancer sequences that reduced PU.1 expression
by 80% resulted in the development of AML (11). In this
model, preleukemic BM had some features that were remi-
niscent of those reported here, including enhanced granu-
lopoiesis and loss of M-CSFR and GM-CSFR expression.
In contrast, these cells continued to express PU.1 targets
Mac-1 and Fc RII/III and had normal numbers of G-CSF–
responsive progenitors; this suggests that distinct processes
are occurring (11). The rapid onset of the neutrophilia (Figs.
2 and 3), the erythromyeloid differentiation capacity of
PU.1-deficient stem cells in chimeric mice in the absence of
detectable disease (Fig. 6), and the appearance of excess
growth factor–dependent granulocyte colonies in vitro
shortly after PU.1 deletion (Fig. 5) suggested that in our
model, the deregulated differentiation occurred indepen-
dently of any subsequent transformation event. Our prelimi-
nary studies of aging PU.1 /  mice revealed that PU.1-defi-
cient mice do develop myeloid leukemia at a high frequency
(unpublished data). However, the resulting leukemias are
heterogeneous in terms of their in vitro growth properties
and ability to transfer the disease to secondary recipients; this
suggests that the role of PU.1 as a tumor suppressor is more
complex than currently appreciated (11, 12). In an attempt
to provide further molecular insights into the role that PU.1
plays in the multipotent progenitors, we analyzed gene ex-
pression in BM lin  cells. PU.1-deficient progenitors had
reduced expression of M-CSFR, GM-CSFR , and IL-7R ,
but not G-CSFR. The normal expression of G-CSFR con-
trasted with the absence of this receptor in PU.1 /  from fe-
tal liver (28, 29, 31), and provided a potential explanation of
the increased granulopoiesis. However, PU.1 /  BM also
showed increased granulocyte colonies in the presence of
IL-3 or IL-3/SCF/EPO which indicated that the expression
of G-CSFR was not solely responsible for the phenotype.
Moreover, at longer time points after PU.1 inactivation, the
relative contribution of G-CSF in driving the proliferation
and differentiation of clonogenic progenitors decreased
compared with IL-3/SCF; this suggested that these factors
were the more important. Unexpectedly, PU.1 also was re-
quired for the expression of the IL-6 and LIF receptor com-
ponents (IL-6R  and gp130) and IL-5R  expression (Fig.
4); this further supported the proposition that PU.1 regulates
the response of progenitors to extrinsic regulatory signals.
We also assessed the expression of a cohort of key transcrip-
tional regulators of early hematopoiesis, several of which—
including IRF-8 and GATA-1—were expressed at lower lev-
els in the absence of PU.1 (Fig. 4 C). In contrast, C/EBP ,
whose expression is essential for the CMP to GMP transi-
tion (40), was increased in PU.1 /  lin– BM cells (Fig. 4 C).
A recent study in PU.1 /  cell lines demonstrated that
C/EBP  is induced by G-CSF signaling and that the ratio
of C/EBP  to PU.1 is crucial to commitment to the granu-
locyte cell fate, potentially providing a candidate mechanism
for the excess granulopoiesis observed in the PU.1 /  tissues
(41). G-CSFR expression already is detectable in the HSC
(42) which makes this G-CSF-C/EBP  proposal in the ab-
sence of balancing PU.1 action an even more attractive hy-
pothesis. In addition to these important regulatory genes, it
was striking that PU.1 also was required for the expression
of several myeloid markers, including Mac-1 (27), Fc RII/
III (24), CD45 (25), and F4/80 (Figs. 2–4). This makes in-
terpretation of flow cytometric data problematic without us-
ing the in vitro clonogenic progenitor approach that is out-
lined here.
The prevailing models of PU.1 function in hematopoie-
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liver cells where lymphoid versus macrophage lineage com-
mitment depends on the graded levels of PU.1 (15, 43). In
contrast, PU.1 expression in myeloid progenitors was pro-
posed not to be required for cell commitment but for the re-
sponse to extrinsic signals once a cell is restricted to a partic-
ular lineage (28, 29, 44, 45). Although this latter model is
consistent with the requirement for PU.1 for the expression
of a number of lineage-specific cytokine receptors, the
grossly deregulated granulopoiesis; absence of de novo lym-
phopoiesis; and the loss of discernable CLP, CMP, GMP, or
MEP populations along with long-term self-renewing he-
matopoietic activity suggests that the predominant develop-
mental role of PU.1 in the adult is to control the balanced
transition of the stem cell through the progressively commit-
ted multipotent progenitor stages.
MATERIALS AND METHODS
Construction and genotyping of PU.1gfp mice. The  PU.1-targeting
construct used the pKW11 vector consisting of a splice acceptor, stop
codons in all reading frames, an IRES, eGFP cDNA, a SV40 polyadenyla-
tion signal, and a PGK-Neor gene. Genomic DNA containing LoxP flanked
exon-5 was cloned in front of the pKW11 insert. Homology arms of 2.6 kb
(5 ) and 3 kb (3 ) were amplified from a PU.1-containing bacterial artificial
chromosome and cloned into the final targeting vector. The linear targeting
vector was introduced into the 3  untranslated region of PU.1 by homolo-
gous recombination in C57BL/6 ES cells. Neomycin-resistant clones were
screened by Southern hybridization using 5  (digested with Eco RI, giving
wild-type 6.6 kb and PU.1gfp 5.3 kb) and 3  (Bgl II wild-type 7.2 kb and
PU.1gfp 5.4 kb) probes. Targeted ES cell clones were injected into BALB/c
blastocysts to obtain chimeric founders. Germ-line transmission was achieved
with two clones. PCR genotyping was performed using the primer combi-
nation: a: 5 -TGGCGCCTACCGGTGGATGTGG-3 , b: 5 -CTGTCT-
GCCACCACCTGCCTACATT-3 , c: 5 -GTGCTTCCTTGGGAGTC-
TGGCGCT-3 , d: 5 -GCACACATGCGTGTTTGTGGATGCT-3 , and
e: 5 -GCAGGCTCGATAGATGCCTTACACC-3 . Primer combination
a/b/c gave PCR fragments of 680 bp (b/c wild type), 512 bp (a/b PU.1gfp),
and 738 bp (b/c PU.1fl). Whereas b/d gave an additional 837-bp deleted
band (b/d PU.1 ), the combination c/d/e gave 466 bp (c/e PU.1gfp) and 565
(d/e PU.1 gfp). Deletion frequency was determined by amplification of ge-
nomic DNA followed by electrophoresis on a 2% agarose gel. Tail DNA of
all genotypes was used as PCR controls in all experiments.
PU.1 conditional deletion and mouse strains. The  PU.1 alleles, flpe
(46), MxCre (20), Deleter-Cre (47), and Ly5.1 congenic mouse lines were
maintained on a C57BL/6 background. The IRES-GFP-Neo cassette of
PU.1gfp was deleted in the germline using flpe. Nonconditional PU.1  mice
were created by breeding PU.1 fl/  with Deleter-Cre. For conditional inacti-
vation PU.1  fl/fl MxCre  mice were weighed and injected i.p. with 12.5
 g/g polyIC (1 mg/ml) two times at 3 d apart with the exception of the
short-term experiments in Fig. 6, where polyIC was injected 36 h and 24 h
before analysis. Deletion frequency was monitored for each experiment us-
ing PCR primers that were outlined above. In all experiments, PU.1  fl/fl
MxCre  mice were used as controls for nonspecific polyIC effects. Mice
were bred and maintained at the Walter and Eliza Hall Institute under Ani-
mal Ethics Committee guidelines.
Analysis of hematologic organs. Peripheral blood cell count and plate-
let counts were determined using a hemocytometer. Single cell suspensions
from femoral BM, spleen, and peritoneal cavity were cytocentrifuged onto
slides, stained with May-Grunwald-Giemsa, and differential cell counts
were performed. Organs were fixed in 10% buffered formalin, embedded in
paraffin, sectioned, and stained with hematoxylin/eosin.
Monoclonal antibodies and flow cytometry. mAbs against the fol-
lowing antigens were used as fluorescent or biotin conjugates for cell stain-
ing and sorting: Ly 5.2 (AL1-4A2), Ly5.1 (A20-1.1), Mac-1 (M1/70), Gr-1
(RA6-8C5), Fc RII/III (2.4G2), B220 (RA3-6B2), CD19 (ID3), Ter119,
CD4 (GK1.5), and CD8 (YTS 169.4) were purified from hybridoma super-
natants and conjugated to fluorochromes. c-kit (2B8), Sca-1 (E13-161-7),
IL7R  (A7R34), CD34 (RAM34), CD71 (C2), and Ly6C (5075–3.6)
were from BD Biosciences. Anti–rat immunoglobulin–Texas red, and phy-
coerythrin- and PerCP-Cy5.5-streptavidin (BD Biosciences) were used as
secondary detection reagents. Sorting and analysis was performed on a
FACStar-Plus or a DiVa high-speed flow cytometer (BD Biosciences). For
cell cycle status, sorted cells were fixed in 70% ethanol overnight, washed,
and stained in cell cycle buffer (0.1% sodium acetate, 0.2% Triton X-100,
10  g/ml RNase A, 50  g/ml propidium iodide).
Isolation of bone marrow precursor populations. The BM precur-
sor populations were isolated by procedures that were described in detail
elsewhere (48). The CMP population was identified as Lin Sca-1 IL-
7R  c-kit CD34 Fc Rlow cells. GMPs were defined as Lin Sca-1 IL-
7R  c-kit Fc R CD34  cells and the MEPs as Lin Sca-1 IL-7R  c-
kit Fc R CD34  cells. HSCs were defined as Lin Sca-1hiIL-7R  c-kithi
and CLPs as Lin Sca-1intIL-7R  c-kitint cells.
Western blotting. Total protein extracts were produced from equivalent
numbers of cells and Western blotting was performed as described previ-
ously (49). Rabbit anti–PU.1 (T21) and goat anti– -actin (I-19) were ob-
tained from Santa Cruz Biotechnology, Inc.
Bone marrow reconstitution. For long-term competitive assays, lethally
irradiated Ly5.1 mice were reconstituted with PU.1fl/fl MxCre  BM mixed
at 3:1 ratio with Ly5.1 competitor. The degree of reconstitution was deter-
mined after 6 wk by analysis of peripheral blood with Ly5.1 and Ly5.2
mAb. PU.1 deletion was induced by polyIC injection as above and the chi-
meras were analyzed 6, 12, and 24 wk later. Because PU.1 regulates CD45
in some lineages, donor cells were defined as Ly5.1  after erythroid
(Ter119 ) cells were excluded.
In vitro clonogenic cultures. BM (2.5   104) and spleen (5   104) cells
were cultured in 1 ml of Dulbecco’s modified Eagle medium containing
0.3% agar and analyzed as described previously (50). Sorted granulocytes
(Gr-1 ) were similarly cultured in liquid medium plus G-CSF for 7 d. The
recombinant cytokines were used at the following final concentrations GM-
CSF, G-CSF, IL-3, M-CSF, LIF (10 ng/ml), SCF and IL-6 (100 ng/ml),
flt3L (500 ng/ml), IFN  (2   103 U/ml), thrombopoietin (50 ng/ml), and
EPO (2I U/ml). After 7 d of incubation, differential colony counts were
performed on fixed whole mount preparations that were stained for acetyl-
cholinesterase, Luxol fast blue, and hematoxylin.
RT-PCR analysis. Semi-quantitative RT-PCR was performed as previ-
ously described (51). For each primer set, a sample of the PCR reaction was
taken at three cycle numbers; each sample was four cycles apart. Amplifica-
tion products all spanned introns and were visualized on 2% agarose gels.
Primer sequences are available upon request.
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